These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17916172)

  • 1. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
    Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
    Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
    Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
    Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.
    Phillips LE; McLintock C; Pollock W; Gatt S; Popham P; Jankelowitz G; Ogle R; Cameron PA;
    Anesth Analg; 2009 Dec; 109(6):1908-15. PubMed ID: 19923520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry.
    Cameron P; Phillips L; Balogh Z; Joseph A; Pearce A; Parr M; Jankelowitz G
    Injury; 2007 Sep; 38(9):1030-8. PubMed ID: 17706654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in the use of recombinant activated factor VII in critical bleeding.
    Willis CD; Cameron PA; Phillips L
    Intern Med J; 2010 Jul; 40(7):486-93. PubMed ID: 19712199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
    Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
    Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry.
    Blatný J; Mathew P; Monagle P; Ovesna P; Fiamoli V
    Blood Coagul Fibrinolysis; 2014 Jun; 25(4):326-32. PubMed ID: 24389586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability and safety of recombinant activated factor VII to control non-haemophilic haemorrhage: investigational experience in 265 children.
    Herbertson M; Kenet G
    Haemophilia; 2008 Jul; 14(4):753-62. PubMed ID: 18445016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of outcomes following recombinant activated FVII use for refractory bleeding during abdominal aortic aneurysm repair.
    Kandane-Rathnayake RK; Willis CD; Beiles CB; Bourke BM; Cameron PA; McCall P; Phillips LE
    Eur J Vasc Endovasc Surg; 2013 Jun; 45(6):617-25. PubMed ID: 23433950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
    Guzzetta NA; Russell IA; Williams GD
    Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of recombinant activated factor VII in randomized clinical trials.
    Levi M; Levy JH; Andersen HF; Truloff D
    N Engl J Med; 2010 Nov; 363(19):1791-800. PubMed ID: 21047223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report).
    Karkouti K; Arellano R; Aye T; Dupuis JY; Kent B; Lee TW; Lin Y; Ralley F; MacAdams C; Mazer CD; Muirhead B; Rheault MR; Rochon A; Syed S; Waters T; Wong B
    Can J Anaesth; 2014 Aug; 61(8):727-35. PubMed ID: 24890696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII.
    Zatta A; Mcquilten Z; Kandane-Rathnayake R; Isbister J; Dunkley S; Mcneil J; Cameron P; Phillips L
    Blood Transfus; 2015 Jan; 13(1):86-99. PubMed ID: 24960661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
    Tomita E; Takase H; Tajima K; Suematsu Y
    Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Off-label use of recombinant factor VII (rFVIIa) in teaching hospitals in Paris in 2010].
    Bardon J; Fink J; de Montblanc J; Bergmann JF; Sarrut B; Benhamou D
    Ann Fr Anesth Reanim; 2013 Oct; 32(10):659-64. PubMed ID: 23953834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
    Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
    Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand.
    Flower O; Phillips LE; Cameron P; Gunn K; Dunkley S; Watts A; Rajbhandari D
    Blood Coagul Fibrinolysis; 2010 Apr; 21(3):207-15. PubMed ID: 20182351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.
    Palmason R; Vidarsson B; Sigvaldason K; Ingimarsson JP; Gudbjartsson T; Sigurdsson GH; Onundarson PT
    Acta Anaesthesiol Scand; 2012 May; 56(5):636-44. PubMed ID: 22489992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.